A phase II clinical trial to be conducted by UCSF and BioGenCell
[California, USA, April 20, 2023] – BioGenCell, the leading personalized cell therapy solution provider, announced today that it has partnered with the University of California San Francisco (UCSF) as part of the company’s phase II clinical trials.
The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischemia (CLTI also known as CLI), a debilitating condition commonly associated with diabetes.
This is part of a worldwide multi-site placebo controlled trial in dozens of patients across North America, Europe and Asia.